Takeda Pharmaceutical (NYSE:TAK) Insider Andrew Stewart Plump Sells 19,651 Shares of Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Andrew Stewart Plump sold 19,651 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $18.49, for a total value of $363,346.99. Following the completion of the sale, the insider owned 261,656 shares in the company, valued at $4,838,019.44. This trade represents a 6.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Andrew Stewart Plump also recently made the following trade(s):

• On Monday, August 10th, Andrew Stewart Plump sold 165,393 shares of Takeda Pharmaceutical stock. The stock was sold at an average price of $17.10, for a total value of $2,828,220.30.

Takeda Pharmaceutical Price Performance

Shares of TAK opened at $18.17 on Friday. The business has a 50-day moving average of $16.79 and a 200-day moving average of $17.18. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.14 and a quick ratio of 0.62. The company has a market capitalization of $58.22 billion, a price-to-earnings ratio of 53.44 and a beta of -0.08. Takeda Pharmaceutical Co. has a 1 year low of $12.99 and a 1 year high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.47 earnings per share for the quarter, topping the consensus estimate of $0.17 by $0.30. The company had revenue of $7.50 billion during the quarter, compared to analysts’ expectations of $7.13 billion. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. As a group, equities research analysts anticipate that Takeda Pharmaceutical Co. will post 1.54 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TAK has been the topic of several research analyst reports. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Weiss Ratings downgraded Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Finally, Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold”.

Institutional Trading of Takeda Pharmaceutical

Several large investors have recently made changes to their positions in TAK. Concurrent Investment Advisors LLC bought a new stake in Takeda Pharmaceutical in the 2nd quarter valued at about $191,000. Natural Investments LLC boosted its holdings in Takeda Pharmaceutical by 3.6% in the second quarter. Natural Investments LLC now owns 17,230 shares of the company’s stock worth $276,000 after acquiring an additional 596 shares in the last quarter. Valeo Financial Advisors LLC bought a new position in Takeda Pharmaceutical in the second quarter worth approximately $163,000. GAMMA Investing LLC grew its stake in Takeda Pharmaceutical by 10.7% in the second quarter. GAMMA Investing LLC now owns 13,837 shares of the company’s stock valued at $222,000 after acquiring an additional 1,338 shares during the period. Finally, Versant Capital Management Inc increased its holdings in shares of Takeda Pharmaceutical by 10.8% during the second quarter. Versant Capital Management Inc now owns 42,686 shares of the company’s stock valued at $684,000 after acquiring an additional 4,169 shares in the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.